DeepMed Research

VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Hepatitis

Interventions: Drug: Methadone
Drug: Dolutegravir

First Posted Date: 2011-11-08

Last Posted Date: 2012-04-09

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 11

Registration Number: NCT01467518

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Completed

Conditions: HIV Infections

First Posted Date: 2011-10-24

Last Posted Date: 2019-09-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 19

Registration Number: NCT01458132

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: dolutegravir 50 mg OAD
Drug: darunavir 800mg OAD
Drug: ritonavir 100mg OAD

First Posted Date: 2011-10-10

Last Posted Date: 2018-01-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 488

Registration Number: NCT01449929

Locations: 🇨🇭
GSK Investigational Site, Zurich, Switzerland

Drug Interaction Study Between Dolutegravir and Prednisone

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Dolutegravir
Drug: Prednisone

First Posted Date: 2011-08-29

Last Posted Date: 2011-11-06

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 12

Registration Number: NCT01425099

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-663068 400 mg
Drug: BMS-663068 1200 mg
Drug: BMS-663068 600 mg
Drug: BMS-663068 800 mg
Drug: Raltegravir 400 mg
Drug: Tenofovir 300 mg
Drug: Ritonavir 100 mg
Drug: Atazanavir 300 mg

First Posted Date: 2011-06-29

Last Posted Date: 2018-11-14

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 254

Registration Number: NCT01384734

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Phase 1

Completed

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions: Drug: Dolutegravir 50 mg tablet
Drug: Dolutegravir 50 mg oral granules

First Posted Date: 2011-06-27

Last Posted Date: 2011-09-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 20

Registration Number: NCT01382238

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Phase 1

Completed

Conditions: Healthy Subjects
Infection, Human Immunodeficiency Virus

Interventions: Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
Drug: Dolutegravir 50 mg
Drug: abacavir 600 mg/lamivudine 300 mg

First Posted Date: 2011-06-06

Last Posted Date: 2011-08-08

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 18

Registration Number: NCT01366547

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Dolutegravir Renal Impairment Study

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Dolutegravir 50 mg

First Posted Date: 2011-05-16

Last Posted Date: 2012-04-30

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT01353716

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Phase 3

Terminated

Conditions: HIV-1

Interventions: Drug: Emtricitabine/tenofovir
Drug: Maraviroc
Drug: placebo for emtricitabine/tenofovir
Drug: darunavir/ritonavir 800/100 mg
Drug: placebo for maraviroc

First Posted Date: 2011-05-02

Last Posted Date: 2016-01-14

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 813

Registration Number: NCT01345630

Locations: 🇺🇸
Circle CARE Center, Norwalk, Connecticut, United States
🇫🇷
CHU de Nantes - Hotel Dieu, Nantes, France
🇺🇸
Health Services Center, Hobson City, Alabama, United States

and more 171 locations

HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University

Completed

Conditions: AIDS
HIV

First Posted Date: 2011-04-20

Last Posted Date: 2014-04-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 8202

Registration Number: NCT01339416

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy